Myopi‐X spectacle lenses vs atropine 0.01% for myopia control: Turkish study

Abstract: The global surge in myopia poses significant health and economic challenges due to associated complications. Current myopia management strategies include atropine eye drops, orthokeratology, special design contact lenses, and myopia‐control spectacle lenses. The Miyopi‐X (Novax®) spectacle lens is a novel peripheral defocus progressive addition lens designed to mitigate myopia progression. This study aims to assess the efficacy of Miyopi‐X spectacle lenses compared to single vision lenses (SV) and atropine 0.01% eye drops in myopia management. Methods: A retrospective study was conducted on patients aged 5–18 years. Clinical records of patients using Myopi‐X lenses, SV lenses, and those receiving atropine 0.01% eye drop treatment between September 1, 2022, and September 30, 2023, were reviewed. Primary outcome measures included cycloplegic spherical equivalent refraction (SE) and axial length (AL) measured at baseline and 12 months. Results: The study included 92 patients: 41 in the Myopi‐X group, 25 in the SV group, and 26 in the atropine group. At 12 months, both Myopi‐X and atropine 0.01% groups exhibited significantly less SE progression than SV lenses ( p < 0.001). No significant difference in SE change was observed between Myopi‐X and atropine 0.01% ( p : 0.90). Similarly, both Myopi‐X and atropine 0.01% groups showed significantly less AL progression than SV lenses at 12 months ( p < 0.001). However, pairwise comparisons revealed a significant difference in AL change between Myopi‐X and atropine 0.01% groups ( p : 0.02), with atropine 0.01% demonstrating better control over axial elongation compared to Myopi‐X lenses. Conclusions : Miyopi‐X lenses and atropine 0.01% are effective in slowing myopic axial elongation. This study represents the first of its kind conducted on Turkish myopic children/adolescents. References Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, et al. Low‐Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double‐Blinded, Placebo‐Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126:113‐124. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123:1036‐42.